The hemostatic material composition contains a polysaccharide having a reactive group that reacts with a protein to form a crosslinking structure and contains a hydrophobic solvent.

A fibrous birth tissue composition fabricated from placental tissue is provided. Methods of processing a mammal’s placental tissue to form a fibrous birth tissue composition are provided. Regenerative methods are also provided.

The invention concerns a pharmaceutical composition comprising a platelet lysate and its use to treat a wound, an anal fissure, vaginal atrophy or a wrinkle.

Embodiments of the technology may involve a method of processing the human donor tissue for administration to a recipient. This method may include the step of contacting the human donor tissue with a backing layer, where the human donor tissue and the backing layer contain a saline solution. This saline solution may include a solvent and a disassociated salt. The method may further include evaporating a portion of the solvent from a surface of the backing layer. The evaporation of the solvent may move a portion of the disassociated salt from the donor tissue to the backing layer. This process may then result in a tissue that is mostly dry and free of salt crystals.

A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In certain embodiments, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue.

An antimicrobial medical dressing provides a combination of antimicrobial agents in various concentrations that protect against microorganisms, absorb exudates, and promote healing. The antimicrobial agents may include compositions of ethanol, hydrogen peroxide, and/or ethylenediaminetetraacetic acid.

The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated.

The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

A sterile, ready-to-use, flowable haemostatic composition comprises a soluble haemostatic agent comprising a plurality of carriers and a plurality of fibrinogen binding peptides immobilised to the carrier; a biocompatible liquid; and particles of biocompatible cross-linked polysaccharide suitable for use in haemostasis and which are insoluble in the biocompatible liquid. Such compositions may be used for the control of bleeding, especially in surgical procedures.

A formulation of foam thermosensitive hydrogel includes a thermosensitive hydrogel including synthetic polymeric material. The thermosensitive hydrogel has properties of changing phase from liquid to solid in high temperature and changing phase from solid to liquid in low temperature. The foam thermosensitive hydrogel having a predetermined surface tension is formed after mixing the thermosensitive hydrogel with air. The foam thermosensitive hydrogel has properties of increased volume and being semisolid. After injecting the foam thermosensitive hydrogel into a human body, the foam thermosensitive hydrogel changes phase form liquid to solid after temperature rises above LCST. The foam thermosensitive hydrogel injected into the human body becomes a solid, physical barrier between an injured site and surrounding tissue, thereby preventing adhesion from forming in the human body. A method of manufacturing foam thermosensitive hydrogel is also provided.